Agios Pharmaceuticals (AGIO) Interest Expenses (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Interest Expenses came in at $32.7 million in Q2 2026, up 565.34% YoY from $4.9 million in Q2 2025, and down 13.4% on a QoQ basis from $37.7 million in Q1 2026.
Agios Pharmaceuticals (AGIO) Interest Expenses (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of Interest Expenses data on file, last reported at $32.7 million in Q2 2026.
- Quarterly Interest Expenses rose 565.34% year-over-year to $32.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $32.7 million (up 70.88% YoY) and the FY2025 annual result came in at $365.6 million, up 32.66% from the prior year.
- Interest Expenses retreated to $32.7 million in Q2 2026, from $37.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $37.7 million in Q1 2026 to a low of $3.8 million in Q1 2022.
- A 5-year average of $8.0 million and a median of $4.7 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses climbed 2.94% — and 2026, when it soared 680.09%.
- Tracing AGIO's Interest Expenses over 5 years: stood at $4.4 million in 2022, then climbed by 2.96% to $4.6 million in 2023, then increased by 2.94% to $4.7 million in 2024, then rose by 4.88% to $4.9 million in 2025, then jumped by 564.26% to $32.7 million in 2026.
- The last three Interest Expenses figures came in at $32.7 million (Q2 2026), $37.7 million (Q1 2026), and $4.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Agios Pharmaceuticals | 2.00 Bn | 1.38 Bn | 41.75 Mn | 32.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.68 Mn |
| Jun 30, 2026 | 32.68 Mn |
| Mar 31, 2026 | 37.73 Mn |
| Mar 31, 2026 | 37.73 Mn |
| Dec 31, 2025 | 4.92 Mn |
| Dec 31, 2025 | 4.92 Mn |
| Sep 30, 2025 | 47.66 Mn |
| Sep 30, 2025 | 47.66 Mn |
| Jun 30, 2025 | 4.91 Mn |
| Jun 30, 2025 | 4.91 Mn |
| Mar 31, 2025 | 4.84 Mn |
| Mar 31, 2025 | 4.84 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 4.68 Mn |
| Sep 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Mar 31, 2024 | 4.65 Mn |
| Mar 31, 2024 | 4.65 Mn |